JP4011479B2 - 早産、胎児感染及び胎児損傷の産前診断用診断試薬及びこれを含む診断キット - Google Patents
早産、胎児感染及び胎児損傷の産前診断用診断試薬及びこれを含む診断キット Download PDFInfo
- Publication number
- JP4011479B2 JP4011479B2 JP2002544659A JP2002544659A JP4011479B2 JP 4011479 B2 JP4011479 B2 JP 4011479B2 JP 2002544659 A JP2002544659 A JP 2002544659A JP 2002544659 A JP2002544659 A JP 2002544659A JP 4011479 B2 JP4011479 B2 JP 4011479B2
- Authority
- JP
- Japan
- Prior art keywords
- mmp
- amniotic fluid
- diagnostic
- fetal
- concentration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 208000005107 Premature Birth Diseases 0.000 title claims description 56
- 239000003153 chemical reaction reagent Substances 0.000 title claims description 19
- 238000009007 Diagnostic Kit Methods 0.000 title claims description 16
- 230000001605 fetal effect Effects 0.000 title description 33
- 208000015181 infectious disease Diseases 0.000 title description 27
- 206010016852 Foetal damage Diseases 0.000 title description 22
- 238000003793 prenatal diagnosis Methods 0.000 title description 6
- 108030001564 Neutrophil collagenases Proteins 0.000 claims description 138
- 102000056189 Neutrophil collagenases Human genes 0.000 claims description 138
- 210000004381 amniotic fluid Anatomy 0.000 claims description 113
- 206010036590 Premature baby Diseases 0.000 claims description 24
- 238000000034 method Methods 0.000 claims description 18
- 239000000758 substrate Substances 0.000 claims description 16
- 208000006399 Premature Obstetric Labor Diseases 0.000 claims description 11
- 102000004190 Enzymes Human genes 0.000 claims description 10
- 108090000790 Enzymes Proteins 0.000 claims description 10
- 238000006243 chemical reaction Methods 0.000 claims description 10
- 239000000126 substance Substances 0.000 claims description 10
- 208000024891 symptom Diseases 0.000 claims description 9
- 239000011159 matrix material Substances 0.000 claims description 7
- 238000004458 analytical method Methods 0.000 claims description 6
- 206010036600 Premature labour Diseases 0.000 claims description 4
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 claims description 4
- 208000026440 premature labor Diseases 0.000 claims description 4
- GEYOCULIXLDCMW-UHFFFAOYSA-N 1,2-phenylenediamine Chemical compound NC1=CC=CC=C1N GEYOCULIXLDCMW-UHFFFAOYSA-N 0.000 claims description 3
- HWTAKVLMACWHLD-UHFFFAOYSA-N 2-(9h-carbazol-1-yl)ethanamine Chemical compound C12=CC=CC=C2NC2=C1C=CC=C2CCN HWTAKVLMACWHLD-UHFFFAOYSA-N 0.000 claims description 3
- LVSPDZAGCBEQAV-UHFFFAOYSA-N 4-chloronaphthalen-1-ol Chemical compound C1=CC=C2C(O)=CC=C(Cl)C2=C1 LVSPDZAGCBEQAV-UHFFFAOYSA-N 0.000 claims description 3
- 206010036595 Premature delivery Diseases 0.000 claims description 3
- SXEHKFHPFVVDIR-UHFFFAOYSA-N [4-(4-hydrazinylphenyl)phenyl]hydrazine Chemical compound C1=CC(NN)=CC=C1C1=CC=C(NN)C=C1 SXEHKFHPFVVDIR-UHFFFAOYSA-N 0.000 claims description 3
- 239000000427 antigen Substances 0.000 claims description 3
- 102000036639 antigens Human genes 0.000 claims description 3
- 108091007433 antigens Proteins 0.000 claims description 3
- 239000007853 buffer solution Substances 0.000 claims description 3
- 239000011521 glass Substances 0.000 claims description 3
- JGVWCANSWKRBCS-UHFFFAOYSA-N tetramethylrhodamine thiocyanate Chemical compound [Cl-].C=12C=CC(N(C)C)=CC2=[O+]C2=CC(N(C)C)=CC=C2C=1C1=CC=C(SC#N)C=C1C(O)=O JGVWCANSWKRBCS-UHFFFAOYSA-N 0.000 claims description 3
- YRNWIFYIFSBPAU-UHFFFAOYSA-N 4-[4-(dimethylamino)phenyl]-n,n-dimethylaniline Chemical compound C1=CC(N(C)C)=CC=C1C1=CC=C(N(C)C)C=C1 YRNWIFYIFSBPAU-UHFFFAOYSA-N 0.000 claims description 2
- 102000002260 Alkaline Phosphatase Human genes 0.000 claims description 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 claims description 2
- 102000003992 Peroxidases Human genes 0.000 claims description 2
- 238000002835 absorbance Methods 0.000 claims description 2
- ZTOJFFHGPLIVKC-CLFAGFIQSA-N abts Chemical compound S/1C2=CC(S(O)(=O)=O)=CC=C2N(CC)C\1=N\N=C1/SC2=CC(S(O)(=O)=O)=CC=C2N1CC ZTOJFFHGPLIVKC-CLFAGFIQSA-N 0.000 claims description 2
- 239000000853 adhesive Substances 0.000 claims description 2
- 230000001070 adhesive effect Effects 0.000 claims description 2
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical group [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 claims description 2
- 239000012528 membrane Substances 0.000 claims description 2
- 229920001220 nitrocellulos Polymers 0.000 claims description 2
- 239000002245 particle Substances 0.000 claims description 2
- 108040007629 peroxidase activity proteins Proteins 0.000 claims description 2
- 229920005990 polystyrene resin Polymers 0.000 claims description 2
- 229920000915 polyvinyl chloride Polymers 0.000 claims description 2
- 238000004445 quantitative analysis Methods 0.000 claims description 2
- 101000973921 Coccidioides posadasii (strain C735) Neutral protease 2 homolog MEP8 Proteins 0.000 claims 1
- 239000000020 Nitrocellulose Substances 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 206010008129 cerebral palsy Diseases 0.000 description 23
- 230000035945 sensitivity Effects 0.000 description 18
- 206010056254 Intrauterine infection Diseases 0.000 description 16
- 206010061218 Inflammation Diseases 0.000 description 13
- 230000004054 inflammatory process Effects 0.000 description 13
- 102000004889 Interleukin-6 Human genes 0.000 description 12
- 108090001005 Interleukin-6 Proteins 0.000 description 12
- 210000003754 fetus Anatomy 0.000 description 12
- 229940100601 interleukin-6 Drugs 0.000 description 12
- 230000002028 premature Effects 0.000 description 12
- 108010015302 Matrix metalloproteinase-9 Proteins 0.000 description 11
- 239000003550 marker Substances 0.000 description 10
- 238000012360 testing method Methods 0.000 description 10
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 9
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 9
- 102100030412 Matrix metalloproteinase-9 Human genes 0.000 description 8
- 238000003745 diagnosis Methods 0.000 description 8
- 210000000440 neutrophil Anatomy 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 206010060937 Amniotic cavity infection Diseases 0.000 description 7
- 229940088598 enzyme Drugs 0.000 description 7
- 230000002757 inflammatory effect Effects 0.000 description 7
- 210000002826 placenta Anatomy 0.000 description 7
- 208000008158 Chorioamnionitis Diseases 0.000 description 6
- 102000029816 Collagenase Human genes 0.000 description 6
- 108060005980 Collagenase Proteins 0.000 description 6
- 108010062466 Enzyme Precursors Proteins 0.000 description 6
- 102000010911 Enzyme Precursors Human genes 0.000 description 6
- 206010006475 bronchopulmonary dysplasia Diseases 0.000 description 6
- 238000010562 histological examination Methods 0.000 description 6
- 208000011580 syndromic disease Diseases 0.000 description 6
- 210000003954 umbilical cord Anatomy 0.000 description 6
- 102000008186 Collagen Human genes 0.000 description 5
- 108010035532 Collagen Proteins 0.000 description 5
- 102000004127 Cytokines Human genes 0.000 description 5
- 108090000695 Cytokines Proteins 0.000 description 5
- 238000002965 ELISA Methods 0.000 description 5
- 208000006816 Neonatal Sepsis Diseases 0.000 description 5
- 208000020241 Neonatal disease Diseases 0.000 description 5
- 208000037129 Newborn Diseases Infant Diseases 0.000 description 5
- 206010035664 Pneumonia Diseases 0.000 description 5
- 230000004913 activation Effects 0.000 description 5
- 238000002669 amniocentesis Methods 0.000 description 5
- 210000001691 amnion Anatomy 0.000 description 5
- 229920001436 collagen Polymers 0.000 description 5
- 229960002424 collagenase Drugs 0.000 description 5
- 210000004700 fetal blood Anatomy 0.000 description 5
- 208000037805 labour Diseases 0.000 description 5
- 230000007246 mechanism Effects 0.000 description 5
- 206010022840 Intraventricular haemorrhage Diseases 0.000 description 4
- 206010040047 Sepsis Diseases 0.000 description 4
- 210000000349 chromosome Anatomy 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 230000028709 inflammatory response Effects 0.000 description 4
- 201000001245 periodontitis Diseases 0.000 description 4
- 230000035935 pregnancy Effects 0.000 description 4
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 102000001776 Matrix metalloproteinase-9 Human genes 0.000 description 3
- 241000204031 Mycoplasma Species 0.000 description 3
- 206010051606 Necrotising colitis Diseases 0.000 description 3
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 3
- 241001148470 aerobic bacillus Species 0.000 description 3
- 210000001136 chorion Anatomy 0.000 description 3
- 210000002808 connective tissue Anatomy 0.000 description 3
- 238000013211 curve analysis Methods 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 208000004995 necrotizing enterocolitis Diseases 0.000 description 3
- 201000006195 perinatal necrotizing enterocolitis Diseases 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 241001148471 unidentified anaerobic bacterium Species 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 2
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 102000035195 Peptidases Human genes 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 239000006161 blood agar Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 238000012790 confirmation Methods 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000000593 degrading effect Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- -1 leukocytes Proteins 0.000 description 2
- 210000004493 neutrocyte Anatomy 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 230000009984 peri-natal effect Effects 0.000 description 2
- 208000028169 periodontal disease Diseases 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 230000029058 respiratory gaseous exchange Effects 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 230000000451 tissue damage Effects 0.000 description 2
- 231100000827 tissue damage Toxicity 0.000 description 2
- 210000004291 uterus Anatomy 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- ZTOJFFHGPLIVKC-YAFCTCPESA-N (2e)-3-ethyl-2-[(z)-(3-ethyl-6-sulfo-1,3-benzothiazol-2-ylidene)hydrazinylidene]-1,3-benzothiazole-6-sulfonic acid Chemical compound S\1C2=CC(S(O)(=O)=O)=CC=C2N(CC)C/1=N/N=C1/SC2=CC(S(O)(=O)=O)=CC=C2N1CC ZTOJFFHGPLIVKC-YAFCTCPESA-N 0.000 description 1
- LOGFVTREOLYCPF-KXNHARMFSA-N (2s,3r)-2-[[(2r)-1-[(2s)-2,6-diaminohexanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxybutanoic acid Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H]1CCCN1C(=O)[C@@H](N)CCCCN LOGFVTREOLYCPF-KXNHARMFSA-N 0.000 description 1
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
- LKDMKWNDBAVNQZ-UHFFFAOYSA-N 4-[[1-[[1-[2-[[1-(4-nitroanilino)-1-oxo-3-phenylpropan-2-yl]carbamoyl]pyrrolidin-1-yl]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-4-oxobutanoic acid Chemical compound OC(=O)CCC(=O)NC(C)C(=O)NC(C)C(=O)N1CCCC1C(=O)NC(C(=O)NC=1C=CC(=CC=1)[N+]([O-])=O)CC1=CC=CC=C1 LKDMKWNDBAVNQZ-UHFFFAOYSA-N 0.000 description 1
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 208000000187 Abnormal Reflex Diseases 0.000 description 1
- 206010000171 Abnormal reflexes Diseases 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 description 1
- 102100022987 Angiogenin Human genes 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000589562 Brucella Species 0.000 description 1
- 101710155857 C-C motif chemokine 2 Proteins 0.000 description 1
- 102100021943 C-C motif chemokine 2 Human genes 0.000 description 1
- 102100032367 C-C motif chemokine 5 Human genes 0.000 description 1
- 108700012434 CCL3 Proteins 0.000 description 1
- 108090000617 Cathepsin G Proteins 0.000 description 1
- 102000004173 Cathepsin G Human genes 0.000 description 1
- 102000000013 Chemokine CCL3 Human genes 0.000 description 1
- 108010055166 Chemokine CCL5 Proteins 0.000 description 1
- 102000016950 Chemokine CXCL1 Human genes 0.000 description 1
- 108010014419 Chemokine CXCL1 Proteins 0.000 description 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
- 208000014085 Chronic respiratory disease Diseases 0.000 description 1
- 108090000317 Chymotrypsin Proteins 0.000 description 1
- 102000012422 Collagen Type I Human genes 0.000 description 1
- 108010022452 Collagen Type I Proteins 0.000 description 1
- 102100027995 Collagenase 3 Human genes 0.000 description 1
- 108050005238 Collagenase 3 Proteins 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 241001453233 Doodia media Species 0.000 description 1
- 102000005593 Endopeptidases Human genes 0.000 description 1
- 108010059378 Endopeptidases Proteins 0.000 description 1
- 208000004232 Enteritis Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 208000003433 Gingival Pocket Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 102000003777 Interleukin-1 beta Human genes 0.000 description 1
- 108090000193 Interleukin-1 beta Proteins 0.000 description 1
- 102000004890 Interleukin-8 Human genes 0.000 description 1
- 108090001007 Interleukin-8 Proteins 0.000 description 1
- 208000007914 Labor Pain Diseases 0.000 description 1
- 208000035945 Labour pain Diseases 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- 102000000380 Matrix Metalloproteinase 1 Human genes 0.000 description 1
- 108010016113 Matrix Metalloproteinase 1 Proteins 0.000 description 1
- 102000005741 Metalloproteases Human genes 0.000 description 1
- 108010006035 Metalloproteases Proteins 0.000 description 1
- 238000011887 Necropsy Methods 0.000 description 1
- 208000036364 Normal newborn Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 108010093965 Polymyxin B Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 206010053879 Sepsis syndrome Diseases 0.000 description 1
- 206010051379 Systemic Inflammatory Response Syndrome Diseases 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 208000036029 Uterine contractions during pregnancy Diseases 0.000 description 1
- 206010072731 White matter lesion Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 102000036861 Zinc-dependent endopeptidases Human genes 0.000 description 1
- 108091006982 Zinc-dependent endopeptidases Proteins 0.000 description 1
- 208000028752 abnormal posture Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 201000000028 adult respiratory distress syndrome Diseases 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 1
- 229960003942 amphotericin b Drugs 0.000 description 1
- 108010072788 angiogenin Proteins 0.000 description 1
- 238000002555 auscultation Methods 0.000 description 1
- 238000011888 autopsy Methods 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 238000009640 blood culture Methods 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 230000006931 brain damage Effects 0.000 description 1
- 231100000874 brain damage Toxicity 0.000 description 1
- 208000029028 brain injury Diseases 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229960002376 chymotrypsin Drugs 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 210000003785 decidua Anatomy 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 229940066758 endopeptidases Drugs 0.000 description 1
- 230000009088 enzymatic function Effects 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000000477 gelanolytic effect Effects 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 210000003731 gingival crevicular fluid Anatomy 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000003601 intercostal effect Effects 0.000 description 1
- 229940096397 interleukin-8 Drugs 0.000 description 1
- XKTZWUACRZHVAN-VADRZIEHSA-N interleukin-8 Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](NC(C)=O)CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N1[C@H](CCC1)C(=O)N1[C@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC(O)=CC=1)C(=O)N[C@H](CO)C(=O)N1[C@H](CCC1)C(N)=O)C1=CC=CC=C1 XKTZWUACRZHVAN-VADRZIEHSA-N 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 230000036244 malformation Effects 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000008774 maternal effect Effects 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 210000001006 meconium Anatomy 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 230000002956 necrotizing effect Effects 0.000 description 1
- 230000004766 neurogenesis Effects 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 230000003239 periodontal effect Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 230000003169 placental effect Effects 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920000024 polymyxin B Polymers 0.000 description 1
- 229960005266 polymyxin b Drugs 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 108010029690 procollagenase Proteins 0.000 description 1
- 229960003387 progesterone Drugs 0.000 description 1
- 239000000186 progesterone Substances 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 239000003642 reactive oxygen metabolite Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 208000008203 tachypnea Diseases 0.000 description 1
- 206010043089 tachypnoea Diseases 0.000 description 1
- 239000007143 thioglycolate medium Substances 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- 230000036266 weeks of gestation Effects 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/689—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to pregnancy or the gonads
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
- C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54366—Apparatus specially adapted for solid-phase testing
- G01N33/54386—Analytical elements
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
- G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
- G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
- G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
- G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
- G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
- G01N2333/96486—Metalloendopeptidases (3.4.24)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/36—Gynecology or obstetrics
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/36—Gynecology or obstetrics
- G01N2800/368—Pregnancy complicated by disease or abnormalities of pregnancy, e.g. preeclampsia, preterm labour
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Cell Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Reproductive Health (AREA)
- Biophysics (AREA)
- Pregnancy & Childbirth (AREA)
- Gynecology & Obstetrics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR10-2000-0069283A KR100425525B1 (ko) | 2000-11-21 | 2000-11-21 | 조산과 태아감염 및 태아손상을 산전 진단하기 위한진단시약 및 진단키트 |
| PCT/KR2001/001306 WO2002042770A1 (en) | 2000-11-21 | 2001-08-01 | Diagnostic agents for the prenatal diagnosis of preterm delivery, fetal infection, and fetal damage, and diagnostic kit containing the same |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2004522942A JP2004522942A (ja) | 2004-07-29 |
| JP2004522942A5 JP2004522942A5 (enExample) | 2005-05-26 |
| JP4011479B2 true JP4011479B2 (ja) | 2007-11-21 |
Family
ID=19700313
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002544659A Expired - Fee Related JP4011479B2 (ja) | 2000-11-21 | 2001-08-01 | 早産、胎児感染及び胎児損傷の産前診断用診断試薬及びこれを含む診断キット |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US7232661B2 (enExample) |
| EP (1) | EP1336103A4 (enExample) |
| JP (1) | JP4011479B2 (enExample) |
| KR (1) | KR100425525B1 (enExample) |
| CN (1) | CN1245626C (enExample) |
| AU (1) | AU2001275820A1 (enExample) |
| WO (1) | WO2002042770A1 (enExample) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2231791C2 (ru) * | 2002-09-26 | 2004-06-27 | Ахмадеева Эльза Набиахметовна | Способ диагностики внутриутробной инфекции новорожденных |
| GB2435511A (en) * | 2006-02-23 | 2007-08-29 | Mologic Ltd | Protease detection |
| GB2435510A (en) | 2006-02-23 | 2007-08-29 | Mologic Ltd | Enzyme detection product and methods |
| GB2435512A (en) | 2006-02-23 | 2007-08-29 | Mologic Ltd | A binding assay and assay device |
| GB2437311A (en) * | 2006-04-07 | 2007-10-24 | Mologic Ltd | A protease detection product |
| CN104645328A (zh) | 2006-10-03 | 2015-05-27 | 建新公司 | TGF-β拮抗物治疗具有罹患支气管肺发育不良风险的婴儿的用途 |
| US8828950B2 (en) * | 2007-05-01 | 2014-09-09 | Cedars-Sinai Medical Center | Caspase inhibitors in the treatment of infection-associated preterm delivery |
| CN104777307B (zh) * | 2008-10-31 | 2019-10-18 | 耶鲁大学 | 先兆子痫检测和治疗的方法和组合物 |
| US20120238469A1 (en) * | 2009-12-08 | 2012-09-20 | Cedars-Sinai Medical Center | Diagnostic biomarker to identify women at risk for preterm delivery |
| EP2686681B1 (en) | 2011-03-17 | 2016-11-16 | Cedars-Sinai Medical Center | Diagnostic biomarker to predict women at risk for preterm delivery |
| CN105324666B (zh) * | 2013-05-16 | 2018-07-27 | 和卓生物科技（上海）有限公司 | 使用来自母体血液的胎儿细胞捕获的胎儿诊断学 |
| US20160130553A1 (en) | 2014-05-15 | 2016-05-12 | Kellbenx Incorporated | PREPARATION OF FETAL NUCLEATED RED BLOOD CELLS (NRBCs) FOR DIAGNOSTIC TESTING |
| US12202890B1 (en) | 2014-11-07 | 2025-01-21 | Kellbenx Incorporated | Antibodies for detection and enrichment of fetal cells and their use |
| CN104498431B (zh) * | 2015-01-23 | 2017-10-20 | 温州市中心医院 | 一种载玻片原位培养羊水细胞及核型处理分析的方法 |
| KR101578526B1 (ko) * | 2015-07-14 | 2015-12-17 | 이화여자대학교 산학협력단 | 32주 미만의 조산 위험성을 예측하기 위한 마커 il-13 및 이의 이용 |
| KR101695347B1 (ko) | 2015-10-12 | 2017-01-11 | 이화여자대학교 산학협력단 | 유전자의 CpG 메틸화 변화를 이용한 조산 위험성 예측용 조성물 및 이의 이용 |
| KR101589673B1 (ko) * | 2015-10-12 | 2016-01-28 | (주)휴레이포지티브 | 시약 키트의 이미지를 통한 감염병 진단 방법 및 장치 |
| US9662257B1 (en) | 2015-11-06 | 2017-05-30 | Amnion Life, LLC | Premature infant amniotic bath incubator |
| CA3046414A1 (en) * | 2016-12-23 | 2018-06-28 | Susanne Pangratz-Fuhrer | Alpha-b crystallin in the diagnosis of neonatal brain damage |
| EP3631460B1 (en) | 2017-05-31 | 2023-11-15 | B.R.A.H.M.S GmbH | Mmp-8 as a marker for identifying infectious disease |
| EP3438668A1 (en) | 2017-08-04 | 2019-02-06 | B.R.A.H.M.S GmbH | Diagnosis and risk stratification of fungal infections |
| EP3971573A1 (en) | 2017-09-13 | 2022-03-23 | B.R.A.H.M.S GmbH | Proadrenomedullin as a marker for abnormal platelet levels |
| EP3502706A1 (en) | 2017-12-20 | 2019-06-26 | B.R.A.H.M.S GmbH | Workflow for risk assessment and patient management using procalcitonin and midregional-proadrenomedullin |
| RU2687486C1 (ru) * | 2018-02-05 | 2019-05-14 | Федеральное государственное бюджетное образовательное учреждение высшего образования Кубанский государственный медицинский университет Министерства Здравоохранения Российской Федерации (ФГБОУ ВО КУбГМУ МЗ РФ) | Способ определения степени риска внутриутробной инфекции плода у женщин, перенесших грипп A(H1N1) в период беременности |
| KR102184911B1 (ko) * | 2019-06-07 | 2020-12-01 | 한림대학교 산학협력단 | miR-548을 함유하는 조산 예방 또는 치료제 조성물 |
| CN111513729B (zh) * | 2020-05-07 | 2021-04-27 | 吉林大学 | 一种高效的产前诊断间期胎儿细胞检测装置 |
| KR102339013B1 (ko) * | 2020-11-16 | 2021-12-14 | 주식회사 옵티바이오 | 양수 검체 내 mmp-8 정량화가 가능한 체외 진단 키트 |
| KR20240083552A (ko) | 2022-12-05 | 2024-06-12 | 주식회사 제이스텍 | 진단키트용 비드의 공급 및 투입장치 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5597700A (en) * | 1994-04-28 | 1997-01-28 | California Research, Llc | Method for detecting free insulin-like growth-factor-binding protein 1 and a test device for detecting the ruptures of fetal membranes using the above method |
| FI98961C (fi) * | 1994-08-26 | 1997-09-10 | Medix Biochemica Ab Oy | Menetelmät ja määritysvälineet parodontaalisairauden aktiivisuuden ja/tai peri-implantiitin ja/tai niiden kohonneen riskin diagnosoimiseksi |
| US5545616A (en) * | 1994-09-22 | 1996-08-13 | Genentech, Inc. | Method for predicting and/or preventing preterm labor |
-
2000
- 2000-11-21 KR KR10-2000-0069283A patent/KR100425525B1/ko not_active Expired - Lifetime
-
2001
- 2001-08-01 CN CNB018192696A patent/CN1245626C/zh not_active Expired - Fee Related
- 2001-08-01 WO PCT/KR2001/001306 patent/WO2002042770A1/en not_active Ceased
- 2001-08-01 JP JP2002544659A patent/JP4011479B2/ja not_active Expired - Fee Related
- 2001-08-01 AU AU2001275820A patent/AU2001275820A1/en not_active Abandoned
- 2001-08-01 US US10/415,763 patent/US7232661B2/en not_active Expired - Fee Related
- 2001-08-01 EP EP01953363A patent/EP1336103A4/en not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| KR20020039458A (ko) | 2002-05-27 |
| CN1245626C (zh) | 2006-03-15 |
| JP2004522942A (ja) | 2004-07-29 |
| AU2001275820A1 (en) | 2002-06-03 |
| KR100425525B1 (ko) | 2004-03-30 |
| CN1476537A (zh) | 2004-02-18 |
| EP1336103A4 (en) | 2007-05-09 |
| US7232661B2 (en) | 2007-06-19 |
| US20040029176A1 (en) | 2004-02-12 |
| WO2002042770A1 (en) | 2002-05-30 |
| EP1336103A1 (en) | 2003-08-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4011479B2 (ja) | 早産、胎児感染及び胎児損傷の産前診断用診断試薬及びこれを含む診断キット | |
| JP6173387B2 (ja) | 羊膜内感染の検出 | |
| Yoon et al. | Amniotic fluid interleukin-6: a sensitive test for antenatal diagnosis of acute inflammatory lesions of preterm placenta and prediction of perinatal morbidity | |
| US20080090759A1 (en) | Methods and kits for predicting risk for preterm labor | |
| CN102792164A (zh) | 预测早产风险的方法 | |
| Pacora et al. | The diagnostic performance of the beta-glucan assay in the detection of intra-amniotic infection with Candida species | |
| US20040014063A1 (en) | Il-6 detection for predicting risks of preterm delivery | |
| WO2014068018A1 (en) | Methods of prognosis and diagnosis of sepsis | |
| Sunagawa et al. | Comparison of biochemical markers and cervical length for predicting preterm delivery | |
| LaShay et al. | Will cervicovaginal interleukin-6 combined with fetal fibronectin testing improve the prediction of preterm delivery? | |
| Gulbiniene et al. | The significance of TNF‐α and MMP‐8 concentrations in non‐invasively obtained amniotic fluid predicting fetal inflammatory response syndrome | |
| US6174664B1 (en) | Screening method for inflammatory diseases using neutrophil defensins and lactoferrin | |
| Torbé et al. | Are vaginal fluid procalcitonin levels useful for the prediction of subclinial infection in patients with preterm premature rupture of membranes? | |
| RU2285926C2 (ru) | Способ прогнозирования угрозы прерывания беременности с ранних сроков гестации | |
| Kumar et al. | Dynamic alteration in the vaginal secretory proteome across the early and mid-trimesters of pregnancy | |
| CN103782176B (zh) | 用于无创性预测或诊断胎膜早破患者的羊水中的炎症和感染的方法 | |
| JP3897117B2 (ja) | 妊娠中毒症の重症度判定と予知方法、および妊娠中毒症における胎児・胎盤機能の評価方法 | |
| JP2008509410A (ja) | 肝線維症の診断方法 | |
| WO2006026557A2 (en) | Methods and kits for predicting risk for peterm labor | |
| Katsura et al. | Amniotic fluid neutrophil gelatinase‐associated lipocalin and L‐type fatty acid‐binding protein in predicting fetal inflammatory response syndrome | |
| Chepanov et al. | Characteristics of autoantibodies associated with recurrent pregnancy loss | |
| Badr et al. | Maternal serum interleukin-6 as a biomarker for early detection of preterm labor | |
| RU2554817C1 (ru) | Способ лабораторной диагностики угрозы прерывания беременности | |
| Ducarme et al. | Efficacy of serum procalcitonin to predict spontaneous preterm birth in women with threatened preterm labour: a prospective observational study | |
| Sonbol et al. | Cystatin C and β2 microglobulin in preeclampsia: a prospective study |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20051027 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20060124 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20060421 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20060501 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20060724 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20070807 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20070905 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 4011479 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100914 Year of fee payment: 3 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110914 Year of fee payment: 4 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110914 Year of fee payment: 4 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120914 Year of fee payment: 5 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120914 Year of fee payment: 5 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130914 Year of fee payment: 6 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313113 |
|
| R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| LAPS | Cancellation because of no payment of annual fees |